In a recent survey of 2,000 UK adults, 34 per cent preferred consulting pharmacists for health advice after researching symptoms, while for those surveyed
specifically from Wales, this figure increased to 35 per cent, according to 2San - a global supplier of healthcare products and solutions.
The survey said women had a higher tendency, with 39 per cent seeking their pharmacist's guidance compared to 29 per cent of men surveyed.
According to the survey findings, over one-fifth of people in the UK are turning to pharmacists instead of their primary care physician or doctor for guidance
and advice with medical symptoms.
"With more than 38 million patients in the UK waiting more than two weeks for a GP appointment, it is unsurprising that 34 per cent of people surveyed asked a
pharmacist for advice over their primary care physician/doctor in the last 12 months," 2san said.
In Wales, over a third of people prefer their community pharmacist for support and advice, while those aged 65 and above still tend to consult their primary care
physician.
Women accounted for 62 per cent of GPhC registrants in 2019, according to the Royal Pharmaceutical Society. Despite representing the majority of pharmacists
in the UK, only 2 per cent of women are pharmacy business owners compared with 13 per cent of men. Also, the majority of senior pharmacy leadership positions are
held by men, with research showing that only 36 per cent of senior pharmacy leaders are women.
Sobha Sharma Kandel, superintendent pharmacist and co-owner of Neem Tree Pharmacy, Abbey Wood, London, quoted these statistics while shedding light on the
representation of female leaders in the field of pharmacy.
So, what is stopping women from reaching leadership positions in the profession? According to Sobha, the barriers hindering female pharmacists from attaining
leadership positions include:
Gender Bias and Stereotypes
Lack of Representation and Role Models
Glass Ceiling and Double Standards
Work-Life Balance Challenges
Imposter Syndrome
Unequal Access to Opportunities
Negotiation and Advocacy Challenges
"There also continue to be gender and ethnicity pay gaps affecting women in pharmacy," said Sobha, who has been advocating for women in pharmacy by being a part
of the Female Pharmacy Leaders Network.
Cutting the red tape that blocks pharmacists to alter the HRT prescription could 'quickly fix' the problem of women unable to access their HRT medicines, the Royal Pharmaceutical Society (RPS) told Daily Mail.
RPS has suggested that allowing pharmacists to prescribe alternative HRT treatment amid nationwide shortage of HRT medicine could help the women who are struggling
to access these medicines.
Thorrun Govind, chair of the English Pharmacy Board, told MailOnline 'changes in prescription rules need to be changed urgently.'
She added, 'For the pharmacists on the ground, they need the ability to get rid of this bureaucracy. When you think about it - who's best able to offer an alternative - that tends to be the pharmacist.'
MailOnline quoted Professor Claire Anderson, president of the Royal Pharmaceutical Society, as said, 'We welcome the Health Secretary meeting with key suppliers and manufacturers to find solutions to the current shortages. But cutting the red tape holding pharmacists back could provide a 'quick fix' that would allow 'women to access their HRT medicines more speedily'.
Over the past two years, the Covid pandemic has resulted in a backlog of elective care within the NHS, with record numbers of patients on waiting lists
across the UK. Despite efforts to catch up after the first wave, subsequent waves have put further strain on an already stretched NHS system.
This has had a tremendous impact on many patients waiting for routine dermatology appointments and, while every effort has been made to see patients with suspected
serious skin cancers within two weeks, this target is not always achieved.
With rising waiting times, pharmacists are increasingly the first port of call for patients suffering with a broad range of skin problems. From acne and rosacea,
eczema or psoriasis, to changing skin lesions or simple insect bites, pharmacists can give helpful advice, allowing some customers to find quick relief to their
skin complaint in mild cases, while directing others to see their GP without delay.
Below is some practical advice that pharmacists can give to their customers with commonly encountered skin complaints.
Acne
Acne is a common skin condition that not only affects teenagers but adults too. It is estimated that up to 40 per cent of women continue to suffer with acne into
their adult years. Acne has been linked to an increased incidence of depression, anxiety and even suicidal ideation.
Patients have reported feeling overlooked and often dismissed in their concerns by health care professionals.
Unfortunately, these issues have been further compounded by delays in being seen and treated due to the ongoing Covid pandemic. Pharmacists are well placed to help
acne patients choose the right skincare. This should consist of lightweight products, such as gel or milky cleansers, with moisturisers in serum, lotion or light
cream preparations. Some acne suitable products are further labelled as non-comedogenic.
Oil-based or occlusive preparations are best avoided. There are many good quality, non-comedogenic sun blocks suited
More than 1000 pharmacies in England, including Boots stores, are now delivering the newly launched NHS Pharmacy First Service.
Launched on Wednesday (31 January), the new service enables pharmacists to provide advice and treatment, if appropriate, for seven common conditions, which
include sinusitis, sore throat, earache, infected insect bite, impetigo, shingles, or an uncomplicated urinary tract infection in women.
Instead of going to a GP surgery, patients can go to their community pharmacists to get treatment for these common conditions, without the need for an appointment.
Patients who may need additional support will be referred to a GP or another healthcare provider by the pharmacist.
Seb James, managing director of Boots UK and ROI, has described their launch of Pharmacy First service as "one of the most significant changes in how we can
serve our customers and patients in our 175-year history."
The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a public consultation on plans to reclassify a locally-applied hormone replacement
therapy product to treat the cause and relieve the symptoms of vaginal atrophy.
The MHRA is proposing that Gina 10 microgram vaginal tablets, containing oestradiol, be made available over the counter as a "self care" product, under the
supervision of a pharmacist.
The Commission on Human Medicines too has advised that the application by Novo Nordisk, which is used to treat vaginal dryness, caused by oestrogen deficiency in
postmenopausal women, can be made available as a pharmacy (P) medicine.
The MHRA has been asking GPs, pharmacists and members of the public for their opinions on whether the tablets can be made available to women aged 50 and over who
have not had a period for at least a year.
If the reclassification goes ahead, pharmacists will be given training materials and a checklist to help them supply the medicine safely.
Boots UK's chief pharmacist has been encouraging people to get a flu vaccination by the end of November to help protect themselves, their loved ones and the
NHS this festive season.
Flu cases in the UK are usually highest in the winter months, from December to March. This year, the UK has seen a rise in cases earlier than usual, and therefore
Claire Nevinson, superintendent pharmacist at Boots, reminds people that it is even more important to get protected early to help reduce the risk of spreading the
virus due to increased mixing at Christmas parties and family get togethers.
Approximately 33 million people are eligible for the free NHS flu jab, including those over 50 years of age, pregnant women and those with medical conditions such as
diabetes or heart disease.
The pharmacy multiple says it offers the winter flu jab service, which is suitable for those eligible for the free NHS flu jab as well as privately, adding that it
has already administered over one million flu vaccinations this season.
Ms Nevinson explains: "December is a time to get together with friends and family to celebrate the month's festivities. It's a good idea to plan ahead to ensure you
have your flu jab, and your COVID-19 booster vaccination if you are eligible, if you've not had them already, this the best way to protect yourself and reduce the
risk of passing the viruses to others.
The Medicines and Healthcare Products Regulatory Agency (MHRA) is considering the reclassification of Aquiette 2.5mg tablets contains oxybutynin hydrochloride that is used to treat women with milder symptoms of overactive bladder from Prescription-Only-Medicine (POM) to Pharmacy (P) medicine.
The agency is encouraging pharmacists, GPs and other health care professionals, the public and women to take part in the reclassification consultation to make a
treatment for overactive bladder available for women without the need for a prescription.
Public consultation on a set of proposals to make Aquiette 2.5mg Tablets (oxybutynin hydrochloride) available from pharmacies will close on 13 May, 2022.
It would be the first time a medicine for the treatment of overactive bladder would be available without prescription, if the reclassification consultation receives positive responses.
After the decision is made to reclassify this treatment, pharmacists will have access to training materials and a checklist to enable them to identify women who can be supplied this medicine safely.
The much-awaited Pharmacy First service has been launched in England, enabling patients to get treatment for seven common conditions from their community
pharmacists without needing to see a GP.
According to NHS England, a total of 10,265 community pharmacies, which is equivalent to more than nine in ten community pharmacies in the country, will be
offering the ground-breaking initiative.
The new scheme allows highly trained pharmacists to give advice and prescription-only medicines for minor ailments including sinusitis, sore throat, earache,
infected insect bite, impetigo, shingles, and uncomplicated urinary tract infections in women (under the age of 65).
With this major expansion of pharmacy services, the NHS is aiming to free up 10 million GP appointments a year while giving the public more choice in where and
how they access care.
In a collaborative effort, the National Health Services England (NHSE) is set to deliver the RSV(respiratory syncytial virus) vaccination programme where
pharmacists alongside other healthcare professionals will play a crucial role in administering the vaccine.
The UK Health Security Agency has announced the launch of the new vaccination programme targeting the respiratory syncytial virus (RSV), set to begin on 1 September
2024.
Along with GPs, NHS England (NHSE) will "commission a number of community pharmacies to deliver the programme", ensuring broad accessibility and coverage to protect
two high-risk groups: older adults and pregnant women.
RSV is an RNA virus related to mumps, measles, and human parainfluenza viruses.
It commonly causes coughs and colds in winter, transmitted through droplets and secretions from close contact with infected individuals.
While most RSV infections are mild, infants under six months and the elderly are particularly susceptible to severe diseases like bronchiolitis and pneumonia,
which can lead to hospitalisation.
Women in the UK will be able to purchase Gina 10 mg vaginal tablets without prescription from September from their local pharmacies, announced the Medicines
and Healthcare products Regulatory Agency (MHRA).
The Hormone Replacement Therapy (HRT) product, Gina 10 microgram vaginal tablets (containing estradiol) are used for the treatment of vaginal symptoms such as
dryness, soreness, itching, burning and uncomfortable sex caused by oestrogen deficiency in postmenopausal women aged 50 years and above who have not had a period
for at least one year.
The decision to reclassify these vaginal tablets follows a safety review by the MHRA, independent advice from the Commission on Human Medicines (CHM), and a public
consultation.
The UK regulator sought views from patients, pharmacists, prescribers and a wide range of stakeholders including the Royal College of Obstetricians & Gynaecologists,
the Faculty of Sexual & Reproductive Healthcare, the British Pharmacopoeia Commission and the British Menopause Society.
Dr Rod Hughes sets out how pharmacists can play a pivotal role in steering people with joint pain towards a prevention programme…
Joint health supplements are big business in the UK, with millions of pounds spent over the counter every year. People turn to these supplements for various reasons,
but most are seeking relief from the symptoms of arthritis, a group of painful long-term conditions thought to affect around 10 million people in this country.
Osteoarthritis (OA) is the most common form of arthritis, affecting around eight million people in the UK. The condition is generally age-related, with joint pain
and stiffness developing as the cartilage between the bones gradually wears away.
OA changes and the inflammation involved causes difficulty moving and considerable pain. Rheumatoid arthritis (RA) tends to affect younger people and is caused by
the body's immune system attacking the joints. As a nation we tend to ignore our joints until they cause us problems, resulting in an increasing number of people
taking long-term analgesics to control the pain or needing surgery to repair knees and hips.
Treatment guidelines followed by doctors in the UK recommend that people with arthritis are advised to maintain a healthy weight and keep physically active, while
strengthening their muscles and protecting any damaged joints during daily activities.
In the parliamentary drop-in-event hosted by Community Pharmacy England last week, Members of Parliament (MPs) questioned the Health Secretary on the rising
issue of medicines supply.
"Eighteen community pharmacists in my constituency are reporting challenges on medicine supplies. What more is the Minister going to do to get a grip of this
situation?", Mike Amesbury MP for Weaver Vale, who was present at the event last week, asked the Health Secretary.
In his response, the Health Secretary, Steve Barclay MP said: "We have a long-standing team in the Department focused on medical supplies, which are a continual
issue; as a matter of routine business, there are often challenges in that area."
The Shadow Pharmacy Minister, Karin Smyth MP, also asked: "People across the country rely on local, accessible pharmacies, but whether it is high street closures
or supply problems leading to the absurd situation where women are phoning or visiting multiple pharmacies for a prescribed dose of hormone replacement therapy and
other drugs…They have repeatedly announced plans to expand the role of community pharmacies but have failed to update legislation that could possibly help. … Why
will they not do so?
HRA Pharma is celebrating the 1st anniversary of Hana, the first type of daily oral contraception available in the UK without a prescription.
The launch of Hana in 2021 followed the historic decision of the Medicines and Healthcare products Regulatory Agency (MHRA) to grant a marketing authorisation
and marked a significant step forward in the women's contraception category.
The company reports that pharmacists have embraced the reclassification and have found merit in using emergency contraception consultations as an opportunity to
educate women on their over-the-counter contraception options.
Alison Slingsby, innovations project manager at HRA Pharma, commented: "We have been delighted with Hana's reception - within weeks of launch, it quickly became
the best-selling mini-pill without prescription, with more than 95 per cent market share, and has maintained this market leading position ever since. We previously
had the experience of switching emergency contraceptive ellaOne to a P medicine, Hana is on track to match and eventually exceed the ellaOne volumes.
Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the
Pharmacy First service, which was launched across England in January 2024.
They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows
pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment.
After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo,
shingles, infected insect bites or uncomplicated urinary tract infections in women.
The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and
Nottingham on the project.
Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's
impact on GPs and the wider NHS, pharmacy services and patients."